污水资源化
Search documents
珠海竞逐百亿级市场机遇 发布水务科技应用场景需求清单
2 1 Shi Ji Jing Ji Bao Dao· 2025-10-22 04:07
水质标准提高、智慧城市建设以及数字经济发展成了驱动智慧水务市场快速增长的核心因素。而珠海尝 试通过战略签约、创新平台揭牌、应用场景发布及开展"揭榜挂帅"等一系列举措,将"场景革命"覆盖至 水务领域。 10月21日,珠海召开了首届水务科技创新大会,珠海水控集团与自然资源部天津海水淡化与综合利用研 究所(简称"天津海淡所")、北京碧水源科技股份有限公司(简称"北京碧水源")现场签订合作协议, 从水源拓展、水质优化、成本控制多方面为市民用水保驾护航。 其中,珠海水控集团与天津海淡所将围绕海水淡化与综合利用、工业用水处理及环境治理三大领域结成 深度战略合作伙伴关系,在推动海水淡化产业高质量发展和规模化利用的同时,重点支撑珠海市海洋经 济创新链、产业链建设,做大做强海洋经济。 而珠海水控集团与北京碧水源则聚焦海水淡化装备国产化、海水产业、高品质饮用水、污水资源化、工 业水处理五大领域建立长期科技创新合作,尝试通过技术升级降低生产成本,以"污水变清水"推动资源 循环,减少优质水消耗,让市民喝上"直饮级"好水、用上"经济水"。 头豹研究院相关报告显示,2024年中国智慧水务市场规模为579.3亿元,预计到2029年中国智慧 ...
碧水源(300070) - 2025年9月23日、24日投资者关系活动记录表
2025-09-24 09:12
Group 1: Wastewater Resource Utilization - Wastewater resource utilization is a core business area, focusing on membrane technology iteration and process innovation [2] - The fifth generation of MBR membrane modules has been developed, with significant breakthroughs in structure and nitrogen removal processes [2] - The Meixi Lake wastewater treatment plant, with a design capacity of 250,000 tons/day, is a representative project, recognized as a national green low-carbon benchmark [2] Group 2: Seawater Desalination - The company is expanding into seawater desalination, previously a minor focus, with current technology matching international leaders [3] - The reverse osmosis membrane products achieve a desalination rate of 99.8%, with annual production capacity reaching 3 million square meters [3] - The Bohai New Area integrated seawater utilization project has a total investment exceeding 500 million yuan, aiming to become a new model for seawater desalination in Hebei Province [3] Group 3: Salt Lake Resource Utilization - Salt lake resource utilization is a new focus area, with the development of specialized adsorbents and integrated technologies [4] - The company has launched projects in Tibet and Qinghai, including a lithium extraction project using titanium-based adsorbents [4] - Future plans include expanding from salt lakes to industrial resource recovery, addressing various raw materials [4] Group 4: Biopharmaceutical Applications - The company has entered the biopharmaceutical sector, developing membranes for protein concentration and virus removal [5] - A professional team has been established, achieving breakthroughs in hollow fiber membrane design and manufacturing [5] - Initial applications include projects in CAR-T cell therapy and traditional Chinese medicine, with high recovery rates reported [5]